New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
08:53 EDTQIHU, STO, SSNLF, CS, IBM, UBS, AAPL, AIG, AMGN, NVS, BA, BLK, DISHOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Dish (DISH) to pull LightSquared bid...Lenders use social media to check borrowers' creditworthiness...A U.S.-EU trade war could break out over online privacy...Hong Kong stock exchange to rethink IPOs after Alibaba views...AIG (AIG) extends expiration of tax asset plan to 2017...REUTERS: Credit Suisse (CS) bets on a turnaround for money-losing U.S. brokerage...BlackRock (BLK), NY attorney general agreement ends analyst surveys...Apple (AAPL), Samsung (SSNLF) CEOs to attend mediation in U.S. patent fight...Boeing (BA) machinists want new vote, allege unfair labor practices...BLOOMBERG: Regulators consider Volcker exemption for smaller banks' CDOs...UBS (UBS) may spin off investment bank...As Norway loosens control, Statoil (STO) looks abroad for deals (Businessweek)...Samsung (SSNLF) sees Galaxy S5 by April, studies eye scanner...FINANCIAL TIMES: Novartis (NVS) facing criminal investigation in Japan over drug advertising...IBM (IBM) to create new $1B Watson business unit...CHINA DAILY: Qihoo 360 (QIHU) denies Alibaba interested in investing...SFGATE: Explosion reported at Amgen (AMGN).
News For DISH;AIG;CS;BLK;AAPL;SSNLF;BA;UBS;STO;NVS;IBM;QIHU;AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
December 8, 2014
07:56 EDTCSRBS asks Credit Suisse, others for Coutts bids by Christmas, Reuters says
Subscribe for More Information
07:03 EDTBLKBlackRock downgraded to Neutral from Positive at Susquehanna
Subscribe for More Information
06:37 EDTAAPLApple rumored to be launching 4-inch iPhone in 2015, Times of India reports
Apple is rumored to be developing a new iPhone with a 4-inch display, The Times of India reports, citing a report from The Electronic Times of Taiwan. According to supply chain sources, the device will launch in 2H15. Reference Link
06:22 EDTAAPLApple price target raised to $135 from $120 at Citigroup
Citigroup raised its earnings estimates for Apple after its field work indicated consumers are increasingly buying the higher memory iPhone 6 and 6+. Citi expects purchasing trends towards higher memory devices to drive stronger sales and margins. It believes consensus estimates are yet to factor in this development. The firm raised its price target for Apple shares to $135 from $120 and keeps a Buy rating on the name. Shares of phone maker closed Friday down 49c to $115.
06:15 EDTSSNLF, AAPLLenovo shipments expected to lead Samsung by 9M in 2015, DigiTimes reports
Lenovo (LNVGY) is estimated to beat Samsung (SSNLF) in mobile device shipments in 2015 by about 9M units, reports DigiTimes Research. Lenovo is set to beat Samsung by about 1M units in 2014 and become the second largest mobile computing device brand vendor worldwide behind Apple (AAPL). DigiTimes Research says Lenovo and Samsung plan to focus on maintaining tablet shipments as demand weakens in 2015. Reference Link
05:43 EDTBABoeing Business Jets, Comlux announces order for two BBJ MAX 8s
Subscribe for More Information
05:42 EDTNVS, AMGNSandoz Phase III data shows filgrastim has similar safety, efficacy as NEUPOGEN
Sandoz, a Novartis (NVS) company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's (AMGN) NEUPOGEN in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy. The study also showed that repeated switching at each cycle between the investigational biosimilar and the originator filgrastim showed no impact on efficacy, safety or immunogenicity. The PIONEER study was a Phase III study designed to compare the efficacy and safety of the investigational biosimilar and the reference product with respect to mean duration of severe neutropenia following Cycle 1 chemotherapy. PIONEER was a randomized, double-blind, four-group, multi-center non-inferiority trial conducted at 27 centers. The trial randomized 218 breast cancer patients receiving neoadjuvant myelosuppressive chemotherapy.
December 7, 2014
18:31 EDTCSCredit Suisse assesses prime brokerage business, Reuters says
Subscribe for More Information
14:38 EDTAMGNAmgen announces new data from Phase 2 BLINCYTO immunotherapy study
Amgen announced new data from the Phase 2 BLAST study which evaluated the bispecific T cell engager, BiTE, immunotherapy BLINCYTO in patients with minimal residual disease, MRD, positive B-cell precursor acute lymphoblastic leukemia, ALL. In the study, 78% of patients who received BLINCYTO experienced a complete MRD response , a measure of eradication of residual disease at the molecular level, after one treatment cycle. Nearly all complete responses occurred within the first treatment cycle. The results from the BLAST study will be featured during the 56th American Society of Hematology Annual Meeting and Exposition press briefing on Saturday, December 6, at 10 a.m. PT and will be presented in an oral session at ASH on Monday, December 8, at 10:30 a.m. PT. "BLINCYTO is the most advanced of Amgen's BiTE immunotherapies, a new and innovative approach that helps the body's own immune system fight cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Achieving molecular complete remission is an important goal in the treatment of ALL, and the data presented at ASH demonstrates that BLINCYTO can produce deep responses in patients that have trace amounts of residual disease." MRD is a state of disease in which the microscopic analysis does not show malignant cells, but more sensitive techniques still detect disease at the molecular level. Patients who have persistent or recurrent MRD after their first therapy have a higher risk of relapse than those with no detectable MRD. In addition to the majority of patients achieving a compete MRD response within one cycle of treatment, 80% achieved a complete MRD response across all cycles. Responses occurred in all subgroups including older patients and patients with high MRD level; no predictive factor for MRD response was identified. In the study, adverse events of all grades occurring in 20% or more patients included pyrexia, tremor, chills, fatigue, nausea, vomiting and diarrhea. Grade =3 AEs occurring in five percent or more patients included neutropenia , pyrexia and tremor. Two fatal AEs occurred on treatment: subdural hemorrhage and pneumonitis in conjunction with influenza. Treatment interruptions due to AEs occurred in 31% of patients.
14:18 EDTAMGNAmgen, Onyx announce detailed results from Phase 3 ASPIRE study of Kyprolis
Subscribe for More Information
14:10 EDTAMGNAmerican Society of Hematology to hold a meeting
Subscribe for More Information
12:26 EDTDISHCBS, DISH reach content carriage agreement
Subscribe for More Information
December 5, 2014
11:23 EDTAAPLOption volume leaders
Subscribe for More Information
09:36 EDTAAPLActive equity options trading
Subscribe for More Information
08:15 EDTQIHUCapital Ventures International reports 6.6% passive stake in Qihoo 360
Subscribe for More Information
07:45 EDTAAPLConsensus on Apple iPhone units could be low, says UBS
Subscribe for More Information
06:41 EDTAAPLApple questions validity of plaintiffs in iPod case, NY Times says
Subscribe for More Information
06:30 EDTIBMIBM CFO defends investment strategy in piece on CNBC
Subscribe for More Information
06:21 EDTSSNLFDRAMeXchange: DRAM spot prices hit 7-month low, DigiTimes says
Subscribe for More Information
06:03 EDTAAPLiOS mobile traffic shows iPhone 6 launch strong, says Piper Jaffray
Piper Jaffray says that according to Quantcast data, Apple's (AAPL) iOS mobile traffic share increased from 60.6% at iPhone 6 launch to 61.4% nine weeks after launch, while Google's (GOOG) Android decreased from 38.4% to 37.5% in the same period. Piper views the iOS mobile traffic share as further evidence that the iPhone 6 launch in the U.S. is off to a strong start. It keeps an Overweight rating on Apple shares with a $135 price target.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use